local_hospital

Explora Group S.R.L.

Address
Strada Humorului 102a, 727525 Scheia, Romania

Explora Group S.R.L. - Immunology and Autoimmune Disease Research

Explora Group S.R.L. is a specialized clinical research center with established expertise in conducting complex immunological and autoimmune disease trials. The center demonstrates proficiency in evaluating novel therapeutic approaches for chronic inflammatory conditions, with particular emphasis on comparative efficacy studies and long-term maintenance of response protocols.

  • Multiple sclerosis relapse prevention and disease-modifying therapies
  • Non-radiographic axial spondyloarthritis remission maintenance strategies
  • Advanced withdrawal-retreatment study designs for autoimmune conditions

The research team at Explora Group has demonstrated capability in managing sophisticated trial designs, including double-blind placebo-controlled withdrawal studies and head-to-head comparative trials. Their portfolio reflects a commitment to advancing treatment paradigms in relapsing multiple sclerosis and inflammatory spondyloarthropathies, with focus on both achieving and maintaining clinical remission. The center's experience encompasses evaluation of novel BTK inhibitors and biologic therapies, positioning them as a valuable partner in neurological and rheumatological clinical development programs.

Site Overview

assignment
2
connected trials
corporate_fare
1
sponsor
science
6
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
1
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 442 other sites in Romania

description
Trial volume
2
Outperforms 37% of sites
public
Therapeutic diversity
2areas
Outperforms 51% of sites
groups
Sponsor diversity
1sponsors
Outperforms 2% of sites

Therapeutic Area Benchmark — Romania

Select a therapeutic area to compare against other sites in Romania.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Romania

Market Share

Country: Romania

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Explora Group S.R.L.

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Randomized, Double-Blind, Parallel-Group Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib ExtensionNovartis Pharma AGPhase IIINot RecruitingJan 2022

IMP list

lock Showing 1 of 6 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Charcoal, Activated1Unknown2022-01-302022-01-30

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.